{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:25Z","timestamp":1778711845112,"version":"3.51.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2319-19"],"award-info":[{"award-number":["2319-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11899-021-00605-9","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T14:08:15Z","timestamp":1611842895000},"page":"8-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-Risk Mantle Cell Lymphoma in the Era of Novel Agents"],"prefix":"10.1007","volume":"16","author":[{"given":"Edward","family":"Nabrinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-5320","authenticated-orcid":false,"given":"Paul B.","family":"Koller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"2","key":"605_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s1535-6108(03)00028-x","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185\u201397. https:\/\/doi.org\/10.1016\/s1535-6108(03)00028-x.","journal-title":"Cancer Cell"},{"issue":"3","key":"605_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3892\/ijo_00000545","volume":"36","author":"L Stefancikova","year":"2010","unstructured":"Stefancikova L, Moulis M, Fabian P, Ravcukova B, Vasova I, Muzik J, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol. 2010;36(3):699\u2013706. https:\/\/doi.org\/10.3892\/ijo_00000545.","journal-title":"Int J Oncol"},{"issue":"45","key":"605_CR3","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(45):18250\u20135. https:\/\/doi.org\/10.1073\/pnas.1314608110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"605_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","volume":"121","author":"I Salaverria","year":"2013","unstructured":"Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(\u2212) mantle cell lymphoma. Blood. 2013;121(8):1394\u2013402. https:\/\/doi.org\/10.1182\/blood-2012-08-452284.","journal-title":"Blood."},{"issue":"6","key":"605_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710\u201325. https:\/\/doi.org\/10.1002\/ajh.25487.","journal-title":"Am J Hematol"},{"key":"605_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2017.05.008","volume":"58","author":"P Martin","year":"2017","unstructured":"Martin P, Ghione P, Dreyling M. Mantle cell lymphoma - current standards of care and future directions. Cancer Treat Rev. 2017;58:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.008.","journal-title":"Cancer Treat Rev"},{"issue":"36","key":"605_CR7","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.22.2554.","journal-title":"J Clin Oncol"},{"issue":"10044","key":"605_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(16)00739-x","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388(10044):565\u201375. https:\/\/doi.org\/10.1016\/s0140-6736(16)00739-x.","journal-title":"Lancet."},{"issue":"28","key":"605_CR9","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/jco.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013\u201323. https:\/\/doi.org\/10.1200\/jco.2005.01.1825.","journal-title":"J Clin Oncol"},{"issue":"6","key":"605_CR10","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","volume":"24","author":"SH Bernstein","year":"2013","unstructured":"Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, et al. A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24(6):1587\u201393. https:\/\/doi.org\/10.1093\/annonc\/mdt070.","journal-title":"Ann Oncol"},{"issue":"13","key":"605_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1701769.","journal-title":"N Engl J Med"},{"issue":"19","key":"605_CR12","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352. https:\/\/doi.org\/10.1182\/blood-2013-11-531327.","journal-title":"Blood."},{"issue":"9873","key":"605_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2.","journal-title":"Lancet."},{"issue":"4","key":"605_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1080\/10428194.2017.1365855","volume":"59","author":"J Drach","year":"2018","unstructured":"Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, et al. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Leukemia & lymphoma. 2018;59(4):896\u2013903. https:\/\/doi.org\/10.1080\/10428194.2017.1365855.","journal-title":"Leukemia & lymphoma"},{"issue":"1","key":"605_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","volume":"48","author":"C Visco","year":"2012","unstructured":"Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012;48(1):68\u201375. https:\/\/doi.org\/10.1016\/j.bcmd.2011.09.007.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"605_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","volume":"25","author":"P Yang","year":"2018","unstructured":"Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5):129\u201340. https:\/\/doi.org\/10.1038\/s41417-018-0022-5.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"605_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7150\/jca.27615","volume":"10","author":"P Sun","year":"2019","unstructured":"Sun P, Chen C, Xia Y, Wang Y, Liu P-P, Bi X-W, et al. Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA. J Cancer. 2019;10(2):323\u201331. https:\/\/doi.org\/10.7150\/jca.27615.","journal-title":"J Cancer"},{"issue":"18","key":"605_CR18","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3390\/ijms20184417","volume":"20","author":"P Klener","year":"2019","unstructured":"Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci. 2019;20(18):4417. https:\/\/doi.org\/10.3390\/ijms20184417.","journal-title":"Int J Mol Sci"},{"key":"605_CR19","doi-asserted-by":"publisher","unstructured":"Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol. 2019;8:2-. https:\/\/doi.org\/10.1186\/s40164-019-0126-0.","DOI":"10.1186\/s40164-019-0126-0"},{"issue":"1","key":"605_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network. Br J Haematol. 2005;131(1):29\u201338. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05716.x.","journal-title":"Br J Haematol"},{"issue":"8","key":"605_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806\u201313. https:\/\/doi.org\/10.1002\/ajh.24797.","journal-title":"Am J Hematol"},{"issue":"11","key":"605_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15(11):1785\u201391. https:\/\/doi.org\/10.1038\/sj.leu.2402272.","journal-title":"Leukemia."},{"issue":"26","key":"605_CR23","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","volume":"132","author":"M Dreyling","year":"2018","unstructured":"Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood. 2018;132(26):2722\u20139. https:\/\/doi.org\/10.1182\/blood-2017-08-737502.","journal-title":"Blood."},{"issue":"4","key":"605_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2559.2005.02323.x","volume":"48","author":"M Parrens","year":"2006","unstructured":"Parrens M, Belaud-Rotureau M-A, Fitoussi O, Carerre N, Bouabdallah K, Marit G, et al. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features. Histopathology. 2006;48(4):353\u201362. https:\/\/doi.org\/10.1111\/j.1365-2559.2005.02323.x.","journal-title":"Histopathology."},{"issue":"10","key":"605_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/ijc.30263","volume":"139","author":"P Klener","year":"2016","unstructured":"Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, et al. Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer. 2016;139(10):2252\u201360. https:\/\/doi.org\/10.1002\/ijc.30263.","journal-title":"Int J Cancer"},{"issue":"2","key":"605_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365. https:\/\/doi.org\/10.1182\/blood-2007-06-095331.","journal-title":"Blood."},{"issue":"9","key":"605_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","volume":"97","author":"J Slotta-Huspenina","year":"2012","unstructured":"Slotta-Huspenina J, Koch I, de Leval L, Keller G, Klier M, Bink K, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica. 2012;97(9):1422\u201330. https:\/\/doi.org\/10.3324\/haematol.2011.055715.","journal-title":"Haematologica."},{"key":"605_CR28","doi-asserted-by":"crossref","unstructured":"Liebers N, Dreger P, Dreyling M, Dietrich S. Risk stratification of mantle cell lymphoma (MCL). Annals of Lymphoma. 2018;2.","DOI":"10.21037\/aol.2018.12.03"},{"issue":"11","key":"605_CR29","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","volume":"109","author":"A Wiestner","year":"2007","unstructured":"Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109(11):4599\u2013606. https:\/\/doi.org\/10.1182\/blood-2006-08-039859.","journal-title":"Blood."},{"issue":"11","key":"605_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","volume":"94","author":"A Mozos","year":"2009","unstructured":"Mozos A, Royo C, Hartmann E, De Jong D, Bar\u00f3 C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555\u201362. https:\/\/doi.org\/10.3324\/haematol.2009.010264.","journal-title":"Haematologica."},{"issue":"14","key":"605_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood-2014-04-569566","volume":"124","author":"J Palomero","year":"2014","unstructured":"Palomero J, Vegliante MC, Rodriguez ML, Eguileor A, Castellano G, Planas-Rigol E, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235\u201347. https:\/\/doi.org\/10.1182\/blood-2014-04-569566.","journal-title":"Blood."},{"key":"605_CR32","doi-asserted-by":"publisher","unstructured":"\u2022 Kuo P-Y, Jatiani SS, Rahman AH, Edwards D, Jiang Z, Ahr K, et al. SOX11 augments BCR signaling to drive MCL-like tumor development. Blood. 2018;131(20):2247\u201355. https:\/\/doi.org\/10.1182\/blood-2018-02-832535. A mouse model showing that overexpression of SOX11 in B cells promotes B-cell receptor signaling and mimics a disease that is similar to human MCL.","DOI":"10.1182\/blood-2018-02-832535"},{"key":"605_CR33","doi-asserted-by":"publisher","unstructured":"\u2022 Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5\u20136):129\u201340. https:\/\/doi.org\/10.1038\/s41417-018-0022-5. Whole Exome sequencing of MCL patients describes the landscape of mutations in MCL. MIPI score and TP53 mutation at diagnosis are prognostic.","DOI":"10.1038\/s41417-018-0022-5"},{"issue":"13","key":"605_CR34","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2019001350.","journal-title":"Blood Adv"},{"issue":"3","key":"605_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","volume":"146","author":"KJ Cheung","year":"2009","unstructured":"Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257\u201369. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07739.x.","journal-title":"Br J Haematol"},{"key":"605_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2015.08.006","volume":"97","author":"TX Lu","year":"2016","unstructured":"Lu TX, Young KH, Xu W, Li JY. TP53 dysfunction in diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2016;97:47\u201355. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.006.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"605_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers11010004","volume":"11","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers (Basel). 2018;11(1):4. https:\/\/doi.org\/10.3390\/cancers11010004.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"605_CR38","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","volume":"103","author":"E Campo","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P, J\u00e4ger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956\u201368. https:\/\/doi.org\/10.3324\/haematol.2018.187583.","journal-title":"Haematologica."},{"issue":"12","key":"605_CR39","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/leu.2010.208","volume":"24","author":"T Zenz","year":"2010","unstructured":"Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24(12):2072\u20139. https:\/\/doi.org\/10.1038\/leu.2010.208.","journal-title":"Leukemia."},{"issue":"10","key":"605_CR40","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","volume":"87","author":"TC Greiner","year":"1996","unstructured":"Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87(10):4302\u201310.","journal-title":"Blood."},{"issue":"7","key":"605_CR41","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1073\/pnas.0510441103","volume":"103","author":"TC Greiner","year":"2006","unstructured":"Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2006;103(7):2352\u20137. https:\/\/doi.org\/10.1073\/pnas.0510441103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"605_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","volume":"41","author":"A Sakhdari","year":"2019","unstructured":"Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, et al. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019;41:38\u201342. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.05.004.","journal-title":"Ann Diagn Pathol"},{"issue":"12","key":"605_CR43","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2011.162","volume":"25","author":"AM Halld\u00f3rsd\u00f3ttir","year":"2011","unstructured":"Halld\u00f3rsd\u00f3ttir AM, Lundin A, Murray F, Mansouri L, Knuutila S, Sundstr\u00f6m C, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25(12):1904\u20138. https:\/\/doi.org\/10.1038\/leu.2011.162.","journal-title":"Leukemia."},{"key":"605_CR44","doi-asserted-by":"publisher","unstructured":"Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, et al. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol. 2020;191. https:\/\/doi.org\/10.1111\/bjh.17063.","DOI":"10.1111\/bjh.17063"},{"issue":"17","key":"605_CR45","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310. https:\/\/doi.org\/10.1182\/blood-2017-04-779736.","journal-title":"Blood."},{"issue":"18","key":"605_CR46","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","volume":"119","author":"L Nygren","year":"2012","unstructured":"Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119(18):4215\u201323. https:\/\/doi.org\/10.1182\/blood-2011-12-400580.","journal-title":"Blood."},{"key":"605_CR47","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue M-H, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417\u201320. https:\/\/doi.org\/10.1182\/blood-2017-07-797019. In patients treated with chemo-immunotherapy high P-53 expression is an independent risk factor for shorter time to treatment failure and shorter overall survival.","DOI":"10.1182\/blood-2017-07-797019"},{"issue":"20","key":"605_CR48","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612\u201321. https:\/\/doi.org\/10.1002\/cncr.29566.","journal-title":"Cancer."},{"issue":"11","key":"605_CR49","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/cncr.31328","volume":"124","author":"IB Greenwell","year":"2018","unstructured":"Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124(11):2306\u201315. https:\/\/doi.org\/10.1002\/cncr.31328.","journal-title":"Cancer."},{"issue":"5","key":"605_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/gcc.20754","volume":"49","author":"B Espinet","year":"2010","unstructured":"Espinet B, Salaverria I, Bea S, Ruiz-Xiville N, Balague O, Salido M, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49(5):439\u201351. https:\/\/doi.org\/10.1002\/gcc.20754.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"605_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gcc.22123","volume":"53","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Terre C, Jardin F, Radford I, Roche-Lestienne C, Penther D, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014;53(1):106\u201316. https:\/\/doi.org\/10.1002\/gcc.22123.","journal-title":"Genes Chromosomes Cancer."},{"issue":"6","key":"605_CR52","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/0008-5472.Can-04-1526","volume":"65","author":"L Hern\u00e1ndez","year":"2005","unstructured":"Hern\u00e1ndez L, Be\u00e0 S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus. Cancer Res. 2005;65(6):2199\u2013206. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-1526.","journal-title":"Cancer Res"},{"issue":"5","key":"605_CR53","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"MH Delfau-Larue","year":"2015","unstructured":"Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604\u201311. https:\/\/doi.org\/10.1182\/blood-2015-02-628792.","journal-title":"Blood."},{"issue":"4","key":"605_CR54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","volume":"149","author":"K Klapproth","year":"2010","unstructured":"Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149(4):484\u201397. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08159.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"605_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbcan.2014.08.006","volume":"1846","author":"T Sewastianik","year":"2014","unstructured":"Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczy\u0144ski P. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim Biophys Acta. 2014;1846(2):457\u201367. https:\/\/doi.org\/10.1016\/j.bbcan.2014.08.006.","journal-title":"Biochim Biophys Acta"},{"key":"605_CR56","doi-asserted-by":"publisher","unstructured":"Wang L, Tang G, Medeiros LJ, Xu J, Huang W, Yin CC, et al. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. 2020:haematol.2019.243071. https:\/\/doi.org\/10.3324\/haematol.2019.243071.","DOI":"10.3324\/haematol.2019.243071"},{"issue":"8","key":"605_CR57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4161\/cc.6.8.4134","volume":"6","author":"VM Sharma","year":"2007","unstructured":"Sharma VM, Draheim KM, Kelliher MA. The Notch1\/c-Myc pathway in T cell leukemia. Cell Cycle. 2007;6(8):927\u201330. https:\/\/doi.org\/10.4161\/cc.6.8.4134.","journal-title":"Cell Cycle"},{"key":"605_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","volume":"12","author":"JC Aster","year":"2017","unstructured":"Aster JC, Pear WS, Blacklow SC. The varied roles of Notch in Cancer. Annu Rev Pathol. 2017;12:245\u201375. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100127.","journal-title":"Annu Rev Pathol"},{"key":"605_CR59","doi-asserted-by":"publisher","unstructured":"Arruga F, Vaisitti T, Deaglio S. The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies. Front Oncol. 2018;8:550-. https:\/\/doi.org\/10.3389\/fonc.2018.00550.","DOI":"10.3389\/fonc.2018.00550"},{"issue":"9","key":"605_CR60","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963\u201371. https:\/\/doi.org\/10.1182\/blood-2011-11-391474.","journal-title":"Blood."},{"issue":"6","key":"605_CR61","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/leu.2013.366","volume":"28","author":"D Koyama","year":"2014","unstructured":"Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(6):1216\u201326. https:\/\/doi.org\/10.1038\/leu.2013.366.","journal-title":"Leukemia."},{"issue":"2","key":"605_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.leu.2403592","volume":"19","author":"M Duechler","year":"2005","unstructured":"Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005;19(2):260\u20137.","journal-title":"Leukemia."},{"issue":"23","key":"605_CR63","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/jco.2012.45.3050","volume":"31","author":"RS Goswami","year":"2013","unstructured":"Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, et al. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013;31(23):2903\u201311. https:\/\/doi.org\/10.1200\/jco.2012.45.3050.","journal-title":"J Clin Oncol"},{"issue":"13","key":"605_CR64","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","volume":"115","author":"J-J Zhao","year":"2010","unstructured":"Zhao J-J, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010;115(13):2630\u20139. https:\/\/doi.org\/10.1182\/blood-2009-09-243147.","journal-title":"Blood."},{"issue":"12","key":"605_CR65","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1158\/1078-0432.Ccr-12-3077","volume":"19","author":"A Navarro","year":"2013","unstructured":"Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, et al. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(12):3121\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-3077.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"605_CR66","doi-asserted-by":"publisher","unstructured":"Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7:F1000 Faculty Rev-136. https:\/\/doi.org\/10.12688\/f1000research.14122.1.","DOI":"10.12688\/f1000research.14122.1"},{"issue":"17","key":"605_CR67","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910\u20139. https:\/\/doi.org\/10.1182\/blood-2017-10-810044.","journal-title":"Blood."},{"issue":"2","key":"605_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/bjh.13042","volume":"167","author":"P Shindiapina","year":"2014","unstructured":"Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol. 2014;167(2):149\u201361. https:\/\/doi.org\/10.1111\/bjh.13042.","journal-title":"Br J Haematol"},{"issue":"6","key":"605_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1306220.","journal-title":"N Engl J Med"},{"key":"605_CR70","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211-e4. https:\/\/doi.org\/10.3324\/haematol.2018.205229. Pooled analysis of multiple trials showing that patients with R\/R MCL treated with ibrutinib had the best responses if they achieved CR or were treated with ibrutinib in the second line.","DOI":"10.3324\/haematol.2018.205229"},{"issue":"3","key":"605_CR71","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430\u20138. https:\/\/doi.org\/10.1111\/bjh.14870.","journal-title":"Br J Haematol"},{"issue":"15","key":"605_CR72","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.31554","volume":"124","author":"MJ Gordon","year":"2018","unstructured":"Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192\u2013200. https:\/\/doi.org\/10.1002\/cncr.31554.","journal-title":"Cancer."},{"key":"605_CR73","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJ, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management, and risk reduction strategies. J Thromb Haemost. 2017;15:835\u201347. https:\/\/doi.org\/10.1111\/jth.13651.","journal-title":"J Thromb Haemost"},{"key":"605_CR74","doi-asserted-by":"crossref","unstructured":"Danilov AV, Persky DO. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. Br J Haematol. 2020.","DOI":"10.1111\/bjh.17184"},{"key":"605_CR75","doi-asserted-by":"publisher","first-page":"S316","DOI":"10.1016\/j.clml.2019.07.291","volume":"19","author":"M Wang","year":"2019","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith S, et al. Long-term follow-up of Acalabrutinib Monotherapy in patients with relapsed\/refractory mantle cell lymphoma. Clinical lymphoma, myeloma and. Leukemia. 2019;19:S316. https:\/\/doi.org\/10.1016\/j.clml.2019.07.291.","journal-title":"Leukemia."},{"key":"605_CR76","doi-asserted-by":"publisher","unstructured":"Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. Ther Adv Hematol. 2019;10:2040620719891356-. https:\/\/doi.org\/10.1177\/2040620719891356.","DOI":"10.1177\/2040620719891356"},{"issue":"4","key":"605_CR77","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1509981.","journal-title":"N Engl J Med"},{"issue":"S2","key":"605_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/hon.15_2629","volume":"37","author":"Y Song","year":"2019","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. ZANUBRUTINIB in patients with relapsed\/refractory mantle cell lymphoma. Hematol Oncol. 2019;37(S2):45\u20136. https:\/\/doi.org\/10.1002\/hon.15_2629.","journal-title":"Hematol Oncol"},{"issue":"8","key":"605_CR79","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320.","journal-title":"J Clin Oncol"},{"key":"605_CR80","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma. New England journal of medicine. 2018;378(13):1211-23. https:\/\/doi.org\/10.1056\/NEJMoa1715519. Pivitol paper showing the combination of Ibrutinib plus venetoclax is highly active in R\/R MCL.","DOI":"10.1056\/NEJMoa1715519"},{"issue":"12","key":"605_CR81","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u201363. https:\/\/doi.org\/10.1182\/blood-2015-10-673145.","journal-title":"Blood."},{"issue":"6","key":"605_CR82","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv111.","journal-title":"Ann Oncol"},{"key":"605_CR83","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor Ibrutinib. N Engl J Med. 2014;370:2286\u201394. https:\/\/doi.org\/10.1056\/NEJMoa1400029.","journal-title":"N Engl J Med"},{"issue":"13","key":"605_CR84","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to Ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437\u201343. https:\/\/doi.org\/10.1200\/JCO.2016.70.2282.","journal-title":"J Clin Oncol"},{"issue":"9","key":"605_CR85","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0098.","journal-title":"Cancer Discov"},{"issue":"1","key":"605_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87\u201392. https:\/\/doi.org\/10.1038\/nm.3435.","journal-title":"Nat Med"},{"key":"605_CR87","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat med. 2019;25(1):119-29. https:\/\/doi.org\/10.1038\/s41591-018-0243-z. This paper describes a novel resistance mechanism of patients treated with ibrutinib\/venetoclax for MCL have resistant disease through SWI-SNF mutations that upregulate BCL-XL.","DOI":"10.1038\/s41591-018-0243-z"},{"issue":"12","key":"605_CR88","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 inhibitor Selinexor overcomes intrinsic Ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol Cancer Ther. 2018;17(12):2564\u201374. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0789-ATR.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"605_CR89","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1080\/10428194.2019.1616190","volume":"60","author":"S Best","year":"2019","unstructured":"Best S, Liu T, Bruss N, Kittai A, Berger A, Danilov AV. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. Leuk Lymphoma. 2019;60(12):2946\u201350. https:\/\/doi.org\/10.1080\/10428194.2019.1616190.","journal-title":"Leuk Lymphoma"},{"key":"605_CR90","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920. https:\/\/doi.org\/10.1038\/ncomms14920.","journal-title":"Nat Commun"},{"key":"605_CR91","doi-asserted-by":"publisher","unstructured":"\u2022 Birkinshaw RW, Gong J-n, Luo CS, Lio D, White CA, Anderson MA, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications. 2019;10(1):2385. https:\/\/doi.org\/10.1038\/s41467-019-10363-1. Paper describes the crystal structure of the G101V mutant complex offers insight into potential targets to treat this resistance mechanism of venetoclax therapy.","DOI":"10.1038\/s41467-019-10363-1"},{"issue":"1","key":"605_CR92","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11912-020-0874-3","volume":"22","author":"L Fletcher","year":"2020","unstructured":"Fletcher L, Nabrinsky E, Liu T, Danilov A. Cell death pathways in lymphoid malignancies. Curr Oncol Rep. 2020;22(1):10. https:\/\/doi.org\/10.1007\/s11912-020-0874-3.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"605_CR93","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nrm.2017.26","volume":"18","author":"CR Clapier","year":"2017","unstructured":"Clapier CR, Iwasa J, Cairns BR, Peterson CL. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 2017;18(7):407\u201322. https:\/\/doi.org\/10.1038\/nrm.2017.26.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"605_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NF\u03baB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9(2):86. https:\/\/doi.org\/10.1038\/s41419-017-0157-6.","journal-title":"Cell Death Dis"},{"issue":"8","key":"605_CR95","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","volume":"93","author":"C Leux","year":"2014","unstructured":"Leux C, Maynadie M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, et al. Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014;93(8):1327\u201333. https:\/\/doi.org\/10.1007\/s00277-014-2049-5.","journal-title":"Ann Hematol"},{"issue":"5","key":"605_CR96","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT lymphoma working party. Bone Marrow Transplant. 2018;53(5):617\u201324. https:\/\/doi.org\/10.1038\/s41409-017-0067-3.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"605_CR97","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/bmt.2016.102","volume":"51","author":"B Tessoulin","year":"2016","unstructured":"Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant. 2016;51(9):1184\u201390. https:\/\/doi.org\/10.1038\/bmt.2016.102.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"605_CR98","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kruger","year":"2014","unstructured":"Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the east German study group Haematology\/oncology (OSHO). Ann Hematol. 2014;93(9):1587\u201397. https:\/\/doi.org\/10.1007\/s00277-014-2087-z.","journal-title":"Ann Hematol"},{"key":"605_CR99","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England journal of medicine. 2020;382(14):1331-42. https:\/\/doi.org\/10.1056\/NEJMoa1914347. Pivitol paper showing that CAR-T cells are highly effective for the treatment of R\/R MCL.","DOI":"10.1056\/NEJMoa1914347"},{"issue":"1","key":"605_CR100","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2019000011","volume":"2019","author":"J Ruan","year":"2019","unstructured":"Ruan J. Molecular profiling and management of mantle cell lymphoma. Hematology. 2019;2019(1):30\u201340. https:\/\/doi.org\/10.1182\/hematology.2019000011.","journal-title":"Hematology."},{"key":"605_CR101","doi-asserted-by":"publisher","unstructured":"Wang ML, Jain P, Lee HJ, Hagemeister FB, Samaniego F, Westin JR, et al. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad\/MTX Is Extremely Potent and Safe in Patients (age \u2264 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. Blood. 2019;134(Supplement_1):3987-. https:\/\/doi.org\/10.1182\/blood-2019-126044.","DOI":"10.1182\/blood-2019-126044"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00605-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T19:30:36Z","timestamp":1618947036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00605-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"14 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"In the past 12\u00a0months, A.V.D. has received consulting fees from AstraZeneca, Abbvie, BeiGene, Genentech, TG Therapeutics, Janssen, Rigel Pharmaceutical, Nurix, Bayer Oncology, Karyopharm and Pharmacyclics and has ongoing research funding from AstraZeneca, Takeda Oncology, Gilead Sciences, Bayer Oncology, Genentech, Verastem Oncology, MEI and Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}